Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
| ▸ | CASP3 | P42574 | 1/20 | 0.30 |
| ▸ | GFER | P55789 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2367310 | 0.88 | ESR1 (0.40) | ALDH1A1HSD17B10CYP1A2HPGDTSHR | |
| SCHEMBL2367765 | 0.80 | AGXT (0.42) | TACR1MEN1KMT2ABACE1 | |
| SCHEMBL8407863 | 0.79 | PPARG (0.38) | TACR1ALDH1A1HSD17B10HPGDTSHR | |
| SCHEMBL2367719 | 0.74 | ALDH1A1 (0.33) | TACR1ALDH1A1HSD17B10CYP1A2HPGD | |
| SCHEMBL2367778 | 0.73 | TACR1 (0.32) | TACR1 | |
| SCHEMBL13365588 | 0.73 | PPARG (0.34) | TACR1ALDH1A1CYP2C19BACE1 | |
| SCHEMBL13365557 | 0.73 | CYP11B1 (0.34) | TACR1BACE1 | |
| SCHEMBL1315036 | 0.69 | IDO1 (0.46) | ALDH1A1TSHRTDP1MAPTCYP2D6 | |
| SCHEMBL2367215 | 0.69 | TACR1 (0.32) | TACR1 | |
| SCHEMBL9476474 | 0.69 | LMNA (0.34) | ALDH1A1TDP1MEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2366785-B1 | OLIGONUCLEOTIDE DERIVATIVE, LABELING AGENT, AND USE OF THE LABELING AGENT | JAPAN SCIENCE & TECH AGENCY (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-8354515-B2 | Oligonucleotide derivative, labeling agent and use for labeling agent | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2013-01-15 | — | — | US | disclosed |
| US-20120126175-A1 | OLIGONUCLEOTIDE DERIVATIVE, LABELING AGENT AND USE FOR LABELING AGENT | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2012-05-24 | — | — | US | disclosed |
| EP-2366785-A1 | OLIGONUCLEOTIDE DERIVATIVE, LABELING AGENT, AND USE OF THE LABELING AGENT | Japan Science And Technology Agency (JP) | 2011-09-21 | — | — | EP | disclosed |
| WO-2010055789-A1 | OLIGONUCLEOTIDE DERIVATIVE, LABELING AGENT, AND USE OF THE LABELING AGENT | 独立行政法人科学技術振興機構 (JP) | 2010-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120126175-A1 | OLIGONUCLEOTIDE DERIVATIVE, LABELING AGENT AND USE FOR LABELING AGENT | UPF1, SPIN4, SRRT | TACR1 1638/4885ALDH1A1 1355/4885HSD17B10 3293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.